GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 32, No. 15_suppl ( 2014-05-20), p. 602-602
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2014
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 8_Supplement ( 2012-04-15), p. 5573-5573
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 5573-5573
    Abstract: Background: Insulin-like growth factor-1 receptor (IGF-1R) is an unusual transmembrane receptor in that both α and β subunits, regulated by IGF-1, translocate from the membrane to the nucleus and then bind to DNA, increasing gene transcription. Insulin receptor substrate-1 (IRS-1), a docking protein for IGF-1R, also traffics to the nucleus and then activates promoters of cell cycle progression genes. We studied the prognostic significance of nuclear and membranous IGF-1R and nuclear IRS-1 in cervical cancer, previously unreported. Methods: We retrospectively reviewed all patients (pts) with stage Ib2-IIb disease who received platinum-based neoadjuvant chemotherapy (NAC) at Hyogo Cancer Center between 2002 and 2009. Age, performance status, FIGO stage, histology, tumor size, pelvic lymph nodes on MRI, squamous cell carcinoma (SCC) antigen level, hemoglobin levels before NAC, chemotherapeutic agents and chemotherapy cycles were evaluated. Paraffin-embedded pretreatment tissue was stained immunohistochemically with an anti-IGF-1Rβ (Cell signaling, MA) or anti-IRS-1 (Millipore, MA) rabbit polyclonal antibody. IGF-1R and IRS-1 expressions were scored from 0 to 3 according to frequency and intensity. All slides were reviewed by a single pathologist. We analyzed prognostic factors associated with overall survival by a Cox proportional-hazards model. Results: A total of 128 pts (median age 57 years) were identified. The majority had stage II (61%) and SCC (69%). Median tumor size was 40 mm. Overall response rate to NAC was 59%, and median follow-up was 34 months. Nuclear and membranous IGF-1R and nuclear IRS-1 expressions were scored as 0/1-2/3 in 49/60/19 pts, 97/12/19 pts, and 65/41/22 pts, respectively. Multivariate analysis revealed that nuclear IGF-1R expression (HR, 2.6; P= .035 for score 1-3 vs. 0) and age & lt;40 (HR, 2.6; P= .026) were independently associated with worse overall survival. Neither membranous IGF-1R nor IRS-1 expression had a prognostic impact on survival. Conclusions: Nuclear IGF-1R is commonly expressed in cervical cancer and is an independent prognostic factor, unlike membranous IGF-1R or nuclear IRS-1. Approaches that block the translocation of IGF-1R from the cell membrane to nucleus might hold promise for the treatment of cervical cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5573. doi:1538-7445.AM2012-5573
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. 5528-5528
    Abstract: 5528 Background: We report efficacy and safety of neoadjuvant cisplatin plus dose-dense paclitaxel (ddTP) within a phase II trial (UMIN-CTR ID: UMIN000006440), designed to investigate recurrence-free survival of neoadjuvant ddTP plus radical hysterectomy followed by adjuvant ddTP without radiotherapy for patients (pts) with stage IB2, IIA2, and IIB cervical cancer, whose driver mutations have been poorly understood. Methods: All enrolled pts received 3 cycles of cisplatin 75 mg/mq on day1 with paclitaxel 80 mg/mq on days 1, 8, and 15 every 21 days. Pathologic complete response (pCR) was defined as no evidence of malignancy in all surgical specimens observed. Using a selected panel of 535 oncogenes (Otogenetics, Norcross, GA), mutations of pretreatment biopsy tissues were analyzed in 6 non-pCR pts with adeno/adenosquamous carcinoma (AC/ASC). Results: Among 51 enrolled pts, 50 were evaluable (40 with squamous cell carcinoma [SCC], 9 with AC/ASC, and 1 with small cell carcinoma). Median age was 52 years (range 30-70), the FIGO stage was IB2 in 14 pts, IIA2 in 3, and IIB in 34. Eighteen pts achieved complete response and 29 pts achieved partial response, with response rate of 94% (47/50). A total of 14 pts (28%; 13 with SCC, 1 with AC) achieved pCR. Grade 3/4 adverse events were neutropenia (34%), nausea (12%), appetite loss (10%), fatigue (6%), and anemia (6%). Febrile neutropenia was uncommon (2%). The analysis of oncogenes revealed that all 6 pts had mutations in the mixed-lineage leukemia (MLL3) gene, a histone methyltransferase, whose mutations have recently been reported in breast, pancreas, and colorectal cancers. Specifically, in MLL3 gene, identical frameshift mutation was found in 2 pts and 2 common non-synonymous point mutations were found in 4 pts, despite no relevance to the ddTP response. No mutations were detected in TP53 and PIK3CA genes. Conclusions: The pCR rate with neoadjuvant ddTP for locally advanced cervical cancer was one of the highest reported in a prospective trial setting. Novel mutations of the MLL3 gene were identified in non-pCR pts with AC/ASC. Clinical trial information: UMIN000006440.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2013
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...